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Abstract 37 
Creutzfeldt-Jakob disease (CJD) is a neurodegenerative disorder caused by prion protein (PrP) misfolding, 38 
clinically recognized by cognitive and motor deficits, electroencephalographic (EEG) abnormalities and 39 
seizures. Its neurophysiological bases are not known. To assess the potential involvement of N-methyl-D-40 
aspartate receptor (NMDAR) dysfunction, we analyzed NMDA-dependent synaptic plasticity in hippocampal 41 
slices from Tg(CJD) mice, which model a genetic form of CJD. Because PrP depletion may result in 42 
functional upregulation of NMDARs, we also analyzed PrP knockout (KO) mice. Long-term potentiation 43 
(LTP) at the Schaffer collateral-commissural synapses in the CA1 area of ?100-day-old Tg(CJD) mice was 44 
comparable to that of wild-type (WT) controls, but there was an inversion of metaplasticity, with increased 45 
GluN2B phosphorylation, indicative of enhanced NMDAR activation. Similar but less marked changes were 46 
seen in PrP KO mice. At ?300 days of age, the magnitude of LTP increased in Tg(CJD), but decreased in 47 
PrP KO mice, indicating divergent changes in hippocampal synaptic responsiveness. Tg(CJD) but not PrP 48 
KO mice were intrinsically more susceptible than WT controls to focal hippocampal seizures induced by 49 
kainic acid. IL-1?-positive astrocytes increased in the Tg(CJD) hippocampus, and blocking IL-1 receptor 50 
signaling restored normal synaptic responses and reduced seizure susceptibility. These results indicate that 51 
alterations in NMDA-dependent glutamatergic transmission in Tg(CJD) mice do not depend solely on PrP 52 
functional loss. Moreover, astrocytic IL-1? plays a role in the enhanced synaptic responsiveness and seizure 53 
susceptibility, suggesting that targeting IL-1? signaling may offer a novel symptomatic treatment for CJD. 54 
 55 
Significance statement 56 
Individuals with Creutzfeldt-Jakob disease (CJD), an incurable brain disorder caused by alterations in prion 57 
protein structure, develop dementia and myoclonic jerks; they are prone to seizures, and have high brain 58 
levels of the inflammatory cytokine IL-1?. Here we show that blocking IL-1? receptors with anakinra, the 59 
human recombinant form of the endogenous IL-1 receptor antagonist used to treat rheumatoid arthritis, 60 
normalizes hippocampal neurotransmission and reduces seizure susceptibility in a CJD mouse model. 61 
These results link neuroinflammation to defective neurotransmission and the enhanced susceptibility to 62 
seizures in CJD, and raise the possibility that targeting IL-1? with clinically available drugs may be beneficial 63 
for symptomatic treatment of the disease. 64 
 65 
  66 
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Introduction 67 
Prion diseases are invariably fatal neurodegenerative disorders of humans and other mammals caused by 68 
misfolding of the cellular prion protein (PrPC), a cell surface glycoprotein of uncertain function (Chiesa, 2015). 69 
Creutzfeldt-Jakob disease (CJD) is the most common form in humans. It can arise sporadically, be 70 
dominantly inherited due to mutations in the PRNP gene encoding PrPC, or acquired by contact with 71 
exogenous PrPSc, the infectious PrP isoform (prion) which propagates by inducing misfolding of host-72 
encoded PrPC (Colby and Prusiner, 2011; Head and Ironside, 2012). 73 
CJD has a stereotyped clinical course. Altered mental function is the initial manifestation, including 74 
dementia, confusion, disorientation, behavior abnormalities and depression of other higher cortical functions. 75 
Later, myoclonic jerks, rigidity, and extrapyramidal and cerebellar abnormalities become prominent. 76 
In about two-thirds of patients, electroencephalography (EEG) detects typical periodic sharp wave 77 
complexes (PSWCs), either lateralized or generalized (Wieser et al., 2006). Epileptiform discharges and 78 
focal motor or generalized seizures may also be observed, typically in the late stage of the disease (Wieser 79 
et al., 2006). Nonconvulsive status epilepticus is sometimes a presenting symptom in CJD (Espinosa et al., 80 
2010). This suggests that changes in neuronal network excitability occur in seizure-prone brain areas. As the 81 
patients near death, they become akinetic, unresponsive, mute and rigid (Head and Ironside, 2012; Puoti et 82 
al., 2012). 83 
The pathogenic mechanisms responsible for this complex symptomatology are not known. Studies in 84 
animal models have suggested several toxic mechanisms activated by abnormally folded PrP that may lead 85 
to neuronal dysfunction and death, including corruption of N-methyl-D-aspartate receptor (NMDAR) activity 86 
(Chiesa, 2015). Increased NMDAR-dependent excitation has been reported in mice inoculated with variant 87 
(v) CJD prions (Ratte et al., 2008), and when PrPSc, or the PrPSc-like PrP106-126 peptide, was exogenously 88 
presented to cultured neurons, NMDAR antagonists blocked the resulting neurotoxicity (Muller et al., 1993; 89 
Perovic et al., 1995; Brown et al., 1997; Resenberger et al., 2011; Thellung et al., 2012).  90 
Loss of a physiological PrPC function in regulating NMDAR activity may also contribute to the pathogenic 91 
process. Genetic PrPC depletion results in increased hippocampal NMDAR-mediated excitation and 92 
glutamate exicitotoxicity (Khosravani et al., 2008). In addition, PrP knockout (KO) mice are reported to be 93 
more susceptible to seizures induced by kainic acid (KA) than wild-type (WT) controls (Walz et al., 1999; 94 
Rangel et al., 2007), perhaps because of facilitated NMDAR-mediated excitation in the hippocampus (Maglio 95 
et al., 2004; Rangel et al., 2009); although this issue remains controversial (Striebel et al., 2013b; Carulla et 96 
al., 2015). 97 
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Deposition of misfolded/aggregated PrP and astro- and micro-gliosis are typical neuropathological 98 
changes in CJD (Sikorska et al., 2012). In addition, CJD brains have high levels of several inflammatory 99 
cytokines, including IL-1? (Sharief et al., 1999; Shi et al., 2013; Llorens et al., 2014). However, it is not clear 100 
which cell population is responsible for the increase in IL-1?, and whether this proinflammatory cytokine 101 
contributes to enhancing NMDAR-mediated glutamatergic transmission (Viviani et al., 2003; Balosso et al., 102 
2008), lowering the threshold for seizures (Vezzani and Viviani, 2015).  103 
We previously generated Tg(CJD) mice expressing the mouse (mo) PrP homolog of the D178N/V129 104 
mutation linked to genetic CJD (Dossena et al., 2008). These mice synthesize a misfolded form of mutant 105 
PrP in their brains, and develop clinical and neuropathological features highly reminiscent of CJD, including 106 
memory and motor deficits, abnormal EEG patterns mimicking the human PSWCs, PrP deposition and 107 
gliosis (Dossena et al., 2008). 108 
The present study provides evidence of dysfunctional NMDA-dependent hippocampal synaptic plasticity 109 
and enhanced seizure susceptibility in Tg(CJD) mice, resulting from a combination of loss and gain of 110 
function of mutant PrP, exacerbated by neuroinflammation. 111 
 112 
Materials and Methods 113 
Experimental design and statistical analysis. All animal experiments were designed in accordance with 114 
the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines (Kilkenny et al., 2010), with a 115 
commitment to refinement, reduction, and replacement, minimizing the numbers of mice, while using 116 
biostatistics to optimize mouse numbers [as used in our previously published peer-reviewed work (Nazzaro 117 
et al., 2012; Bouybayoune et al., 2015; Trusel et al., 2015; Iori et al., 2017)]. Thus, for statistical validity, we 118 
used 5-10 mice for electrophysiology, 6-10 for analysis of KA-induced seizures, and 4-10 for reverse 119 
transcription quantitative real-time PCR (RT-qPCR), biochemical analysis and histology (the number of mice 120 
used in each experiment is reported in the figure legends). No sex-related differences in the Tg(CJD) 121 
phenotype were observed, so both male and female mice were used for RT-qPCR, biochemistry and 122 
histology. Males were used for electrophysiology and analysis of hippocampal seizures, to avoid variations 123 
due to ovarian cycles in females (Mejías-Aponte et al., 2002; Twele et al., 2016). Simple randomization was 124 
used for treatment allocation. Blinding was applied to treatment administration and data analysis. 125 
For each variable, differences between the groups were assessed using independent samples Student's t 126 
test, one-way analysis of variance (ANOVA), two-way ANOVA (genotype and/or drug treatment as 127 
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independent factors) followed by Tukey’s, Mann-Whitney or Holm-Sidak’s post hoc analysis when 128 
appropriate (details are reported in the figure legends). Synaptic plasticity data were analyzed with one-way 129 
ANOVA for repeated measures (RM1W) or two-way ANOVA for repeated measures (RM2W) followed by 130 
Tukey’s post hoc analysis; n indicates number of recordings.  131 
Mice. Production of Tg(CJD) mice, expressing moPrP D177N/V128 tagged with an epitope for monoclonal 132 
antibody 3F4 has already been reported (Dossena et al., 2008). We used mice of the Tg(CJD-A21+/-)/Prnp0/0 133 
line expressing 3F4-tagged D177N/V128 PrP at ?1X, that had been backcrossed for more than ten 134 
generations with an inbred colony of Zürich I Prnp0/0 mice (Bueler et al., 1992) with a pure C57BL/6J 135 
background (C57BL/6J/Prnp0/0; European Mouse Mutant Archive, Monterotondo, Rome, Italy; 136 
RRID:IMSR_EM:01723). The status of the transgene was determined by PCR (Dossena et al., 2008). PrP 137 
KO mice were nontransgenic littermates of Tg(CJD-A21+/-)/Prnp0/0 mice. Age-matched C57BL/6J (WT) mice 138 
were purchased from Envigo (http://www.envigo.com/products-services/research-models-139 
services/models/research-models/mice/inbred/c57bl-6-inbred-mice/c57bl-6jrcchsd/). Mice were housed at 140 
constant room temperature (23°C) and relative humidity (60 ± 5%) with free access to food and water and a 141 
fixed 12-h light/dark cycle. To reduce experimental variability due to different husbandry conditions, WT mice 142 
purchased from Envigo were housed in the same animal room as Tg(CJD) and PrP KO mice for from at least 143 
two weeks to several months. 144 
Procedures involving animals and their care were conducted in conformity with the institutional guidelines 145 
at the IRCCS – Mario Negri Institute for Pharmacological Research in compliance with national (D.lgs 146 
26/2014; Authorization no. 19/2008-A issued March 6, 2008 by Ministry of Health) and international laws and 147 
policies (EEC Council Directive 2010/63/UE; the NIH Guide for the Care and Use of Laboratory Animals, 148 
2011 edition). They were reviewed and approved by the Mario Negri Institute Animal Care and Use 149 
Committee, which includes ad hoc members for ethical issues, and by the Italian Ministry of Health (Decreto 150 
no. 62/2012-B and 212/2016-PR). Animal facilities meet international standards and are regularly checked 151 
by a certified veterinarian who is responsible for health monitoring, animal welfare supervision, experimental 152 
protocols and review of procedures. 153 
Determination of NMDARs on post-synaptic density (PSD). Subcellular fractionation of the mouse 154 
hippocampus was as described (Balducci et al., 2010). Tissue was homogenized in ice-cold 0.32 M sucrose 155 
containing 1 mM Hepes, 1mM MgCl2, 1 mM NaHCO3, 0.1 mM, PMSF, at pH 7.4, with a complete set of 156 
protease inhibitors (SigmaFast, Sigma-Aldrich) and phosphatase inhibitors (PhosSTOP, Roche Life Science). 157 
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The homogenized tissue was centrifuged at 1,000 x g for 5 min and the supernatant was centrifuged at 158 
13,000 x g for 15 min to obtain a crude membrane fraction. The pellet was then resuspended in 1 mM Hepes 159 
containing protease and phosphatase inhibitors, and centrifuged at 100,000 x g for 1 h. The resulting pellet 160 
was resuspended in a buffer containing 75 mM KCl, protease and phosphatase inhibitors and 1% Triton-X 161 
100 and centrifuged at 100,000 x g for 1h. The final pellet was homogenized in a glass-glass Potter 162 
homogenizer in 20 mM Hepes with protease and phosphatase inhibitors; this fraction, referred to as the 163 
Triton-insoluble fraction (TIF), was stored at -80°C. The protein composition of this preparation was tested 164 
for the absence of the presynaptic marker synaptophysin and enrichment in PSD proteins. Proteins (10 ?g) 165 
were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 166 
electrophoretically transferred to poly-vinylidene fluoride (PVDF) membranes. The membranes were blocked 167 
for 1 h in 5% non-fat dry milk in Tris-buffered saline 0.1 M, pH 7.4, containing 0.01% Tween 20 (TTBS), then 168 
incubated with the primary antibody diluted in blocking solution, with the exception of anti-phospho-Tyr1472 169 
GluN2B, which was diluted in TTBS containing 5% bovine serum albumin (BSA). The antibodies were: 170 
mouse monoclonal anti-GluN1 (1:1,000; Synaptic System RRID:AB_2113443), rabbit polyclonal anti-171 
phospho-Tyr1472 GluN2B (1:700; Thermo Scientific RRID: AB_325370), rabbit polyclonal anti-GluN2A 172 
(1:2,000; Molecular Probes RRID:AB_2536209), anti-GluN2B (1:2,000; Molecular Probes 173 
RRID:AB_2536210), mouse monoclonal anti-PSD95 (1:10,000; NeuroMab RRID:AB_10698024 ), mouse 174 
monoclonal anti-?-actin (1:20,000; Millipore RRID:AB_2223041). After thorough rinsing in TTBS, the blots 175 
were incubated with horseradish peroxidase-conjugated secondary antibodies, revealed using enhanced 176 
chemiluminescence (Luminata Forte, Millipore) and visualized by a Biorad XRS image scanner. Quantity-177 
One software (Bio-Rad) was used for quantitative densitometry of protein bands.  178 
Histology. Mice were deeply anesthetized by intraperitoneal injection of 100 mg/kg ketamine hydrochloride 179 
and 1 mg/kg medetomidine hydrochloride (Alcyon), and perfused through the ascending aorta with 180 
phosphate buffered saline (PBS 0.05 M; pH 7.4) followed by 4% paraformaldehyde (PFA) in PBS. Brains 181 
were removed, post-fixed, cryoprotected and frozen at -80°C. Sections were cut throughout the septo-182 
temporal aspects of the hippocampus using a Leica cryostat and incubated for 1 h at RT with 10% normal 183 
goat serum (NGS), 1% Triton X-100 in TBS 0.1 M, pH 7.4, then overnight at 4°C with rabbit polyclonal anti-184 
GFAP antibody (Dako; 1:2,500 RRID:AB_10013382), rat polyclonal anti-CD11b (Serotec; 1:1,000 185 
RRID:AB_321292), goat polyclonal anti-IL-1? (Santa Cruz; 1:200 RRID:AB_2124627), followed by 186 
visualization with the Vectastain ABC kit (Vector), with 3,3’ diaminobenzidine (DAB) (or nickel-intensified 187 
DAB for IL-1?) as chromogen. The TSA Cyanine 5 System (Perkin Elmer) was used for immunoflorescent 188 
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staining of IL-1?. Anti-rat (RRID:AB_141709) and anti-rabbit IgG Alexa 488 (RRID:AB_143165) (1:500, 189 
Molecular Probes) were used for immunoflorescent staining of CD11b and GFAP, respectively. Sections 190 
were reacted with 2??g/mL Hoechst 33258 (Molecular probes RRID:AB_2651133) to stain the nuclei. Slices 191 
were matched at comparable antero-posterior and dorso-ventral levels for comparison of the different 192 
experimental groups. 193 
Reverse transcription quantitative real-time PCR (RT-qPCR). Total RNA from the mouse hippocampus 194 
was extracted using the SV Total RNA Isolation System (Promega) according to the manufacturer’s 195 
instructions; 1-2 ?g of RNA was reverse transcribed with the High-Capacity cDNA Kit (Life Technologies) 196 
and cDNA amplified by a 7900 HT Sequence Detection System (Life Technologies). Samples were always 197 
processed in triplicate. The relative gene expression was calculated by the formula 2(−??Ct) using a defined 198 
group as reference (2(−??Ct) = 1). The primer sequences were: 5’-CTCCATGAGCTTTGTACAAGG-3’ for IL-199 
1? forward and 5’-TGCTGATGTACCAGTTGGGG-3’ for IL-1? reverse; 5’-AGGTCGGTGTGAACGGATTTG-200 
3’ for GAPDH forward and 5’-TGTAGACCATGTAGTAGTTGAGGTCA-3’ for GAPDH reverse (De Simoni et 201 
al., 2000). 202 
Electrophysiology. Male mice were anesthetized with isofluorane and decapitated, and their brains were 203 
transferred to ice-cold dissecting artificial cerebrospinal fluid (aCSF) containing 87 mM NaCl, 75 mM sucrose, 204 
2.5 mM KCl, 1.25 mM NaH2PO4, 7 mM MgCl2, 0.5 mM CaCl2, 25 mM NaHCO3 and 25 mM D-glucose, 205 
saturated with 95% O2 and 5% CO2 (Bischofberger et al., 2006). Oblique coronal sections (350 ?m thick) 206 
were cut using a Vibratome 1000S slicer (Leica), then transferred to aCSF containing 115 mM NaCl, 3.5 mM 207 
KCl, 1.2 mM NaH2PO4, 1.3 mM MgCl2, 2 mM CaCl2, 25 mM NaHCO3, and 25 mM D-glucose and aerated 208 
with 95% O2 and 5% CO2. After 15 min at 32°C, slices were kept at 22-24°C. During experiments, slices 209 
were continuously superfused with aCSF at a rate of 2 mL/min at 28°C. 210 
Extracellular recordings of field postsynaptic potentials (fPSP) were obtained in the CA1 stratum radiatum, 211 
using glass micropipettes filled with aCSF. Stimuli (50-160 ?A, 50 ?s) to excite Shaffer collaterals were 212 
delivered through a bipolar twisted tungsten electrode placed 400 ?m from the recording electrode. LTP was 213 
induced using the following theta burst stimulation protocol (TBS): 10 trains (4 pulses at 100 Hz) at 5 Hz, 214 
repeated twice with a 2-min interval. To induce metaplasticity, we applied a priming low-frequency 215 
stimulation protocol (LFS, 10-Hz, 10 pulses repeated twice, separated by 1 second) delivered 25 min before 216 
TBS (Costello et al., 2012). The magnitude of synaptic plasticity was evaluated by comparing the fPSP 217 
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normalized slopes from the last 5 min of baseline recordings with those 18-26 min after LFS or 35-45 min 218 
after TBS planned comparison.  219 
Mouse model of seizures. Male mice (6-10) were surgically implanted under general gas anesthesia (1-3% 220 
isoflurane in O2) and stereotaxic guidance (Iori et al., 2013). Two nichrome-insulated bipolar depth 221 
electrodes (60 ?m OD) were implanted bilaterally into the dorsal hippocampus (from bregma, mm: nose bar 222 
0; anteroposterior –1.8, lateral 1.5 and 2.0 below dura mater). A 23-gauge cannula was unilaterally 223 
positioned on top of the dura mater and glued to one of the depth electrodes for the intrahippocampal 224 
injection of KA (Balosso et al., 2008; Iori et al., 2013, 2017). The electrodes were connected to a multipin 225 
socket and, together with the injection cannula, were secured to the skull with acrylic dental cement. KA 226 
(Sigma-Aldrich, Saint Louis, MO, USA) was injected intrahippocampally in freely moving mice, seven days 227 
after surgery (Iori et al., 2013). KA 7 ng in 0.5 ?L was dissolved in 0.1 M PBS, pH 7.4, and injected 228 
unilaterally in the dorsal hippocampus in freely moving mice using a needle protruding 2.0 mm from the 229 
bottom of the guide cannula. The needle was left in place for one more minute to avoid backflow through the 230 
cannula. This dose of KA induces EEG ictal episodes in the hippocampus in 100% of mice with no mortality 231 
(Iori et al., 2013). Human recombinant IL-1 receptor antagonist (anakinra) (Biovitrum AB, Stockolm, Sweden) 232 
was diluted in sterile saline and bilaterally injected intracerebroventricularly (0.5 ?g/0.5 ?l/side) in mice, 10 233 
min before KA. For injection of saline or anakinra, mice were implanted with two additional cannulae 234 
bilaterally on top of the dura mater. 235 
EEG activity was recorded using the Twin EEG Recording System (version 4.5.3.23) connected with a 236 
Comet AS-40 32/8 Amplifier (sampling rate 400 Hz, high-pass filter 0.3 Hz, low-pass filter 70 Hz, sensitivity 237 
2000 mV/cm; Grass-Telefactor, West Warwick, R.I., USA). Digitized EEG data were processed using the 238 
Twin record and review software. EEG was recorded for 30 min before KA injection to assess baseline 239 
activity, and for 180 min after KA. At least one 30-min recording similar to baseline was required before 240 
ending the experiment. 241 
Ictal episodes are characterized by high-frequency (7-10 Hz) and/or multispike complexes and/or high-242 
voltage (700 ?V-1.0 mV) synchronized spikes occurring simultaneously in the injected and contralateral 243 
hippocampi. Seizure activity was quantified by measuring the number and total duration of seizures 244 
(summing up the duration of each ictal episode during the EEG recording). Seizures occurred with an 245 
average latency of about 10 minutes from KA injection, then recurred for about 120 min, and were 246 
associated with motor arrest of the mice.  247 
 248 
  9 
Results 249 
Tg(CJD) mice show an inversion of synaptic metaplasticity associated with alterations in NMDAR 250 
composition. The Tg(CJD) mice we used express mutant PrP at a level similar to that of endogenous PrP in 251 
WT mice, on a PrP KO genetic background (C57BL/6J/Prnp0/0); therefore they express transgenic but not 252 
endogenous WT PrP (Dossena et al., 2008). They develop deficits in spatial working memory between 200 253 
and 300 days of age; progressive motor dysfunction, first detectable in the accelerating Rotarod test 254 
between 300 and 350 days; overt clinical signs, such as ataxia, kyphosis and foot clasp reflex, by ?450 days; 255 
and die prematurely at ?700 days (Dossena et al., 2008; Senatore et al., 2012). 256 
We examined synaptic NMDA-dependent long-term plasticity at Schaffer collateral-commissural 257 
synapses in the CA1 area on ex vivo brain slices from presymptomatic ?100-day-old Tg(CJD) mice, non-258 
transgenic PrP KO littermates, and age-matched C57BL/6J (WT) controls. We first examined the ability of 259 
CA3-CA1 synapses to undergo long-term potentiation (LTP). Theta burst stimulation (TBS) resulted in robust 260 
LTP in all groups of mice (% of baseline, WT 134 ± 6; PrP KO 143 ± 8; Tg(CJD) 144 ± 10; n = 7-9, p < 0.05; 261 
Figure A). 262 
Pre-activation of various intracellular signaling pathways before the delivery of a plasticity induction 263 
protocol can prime hippocampal synapses by modifying NMDAR activity (Blitzer et al., 1998; Lu et al., 1998; 264 
Huang et al., 2001). This priming inhibits the subsequent induction of LTP (MacDonald et al., 2006), a 265 
process conceptualized as synaptic metaplasticity (Hulme et al., 2013). When we investigated metaplasticity 266 
at CA3-CA1 synapses of WT mice, we found that a low-frequency (10 Hz) priming stimulus (LFS) did not 267 
change basal neurotransmission (p > 0.05), but prevented the LTP after TBS (100 ± 3% of baseline, n = 7, p 268 
> 0.05; Figure 1B), consistent with previous findings (Balducci et al., 2010). Like in WT mice, LFS priming did 269 
not significantly affect basal synaptic responsiveness in Tg(CJD) and PrP KO animals (p > 0.05) but failed to 270 
inhibit LTP induction in Tg(CJD) (152 ± 11%, n = 9, p < 0.05), and to a lesser extent in PrP KO mice (125 ± 271 
6%, n = 10, p < 0.05; Figure 1B). 272 
Hippocampal metaplasticity depends on changes in the localization and composition of postsynaptic 273 
NMDARs triggered by the priming stimulation (Christie et al., 1995; Gisabella et al., 2003). The inversion of 274 
metaplasticity in Tg(CJD) and PrP KO mice raises the possibility that the composition of NMDARs may be 275 
constitutively altered in these mice, impairing further changes after priming. To test this, we analyzed 276 
NMDAR subunit composition in hippocampal post-synaptic density (PSD)-enriched fractions by 277 
immunoblotting. We found no changes in the total levels of GluN2A, GluN2B and GluN1, but a significant 278 
increase in phospho-Tyr1472 GluN2B in Tg(CJD) mice (Figure 2), which is the phosphorylated isoform that 279 
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potentiates NMDA-induced Ca2+ influx. The level of phospho-Tyr1472 GluN2B in PrP KO mice was 280 
intermediate between that of WT and Tg(CJD) mice (Figure 2C). 281 
These results indicate abnormal hippocampal NMDAR trafficking in the PSD fractions, with an increase in 282 
GluN2B synaptic expression in Tg(CJD) and, to a lesser extent, in PrP KO mice. This correlates well with the 283 
impairment in synaptic metaplasticity, which is also more evident in Tg(CJD) mice. 284 
Tg(CJD) mice show age-dependent increases in IL-1? levels in the hippocampus. There is evidence 285 
that interleukin-1? (IL-1?) promotes Src family kinase (SFK)-mediated Tyr1472 phosphorylation of GluN2B 286 
(Viviani et al., 2003), and its brain levels are high in CJD (Sharief et al., 1999; Shi et al., 2013; Llorens et al., 287 
2014). We investigated IL-1? expression in the hippocampus of Tg(CJD) mice at presymptomatic (60 and 288 
120 days), early (240 days) and advanced (> 400 days) symptomatic stages of their illness (Dossena et al., 289 
2008; Senatore et al., 2012). Immunohistochemistry with an anti-glial fibrillary acid protein (GFAP) antibody 290 
confirmed the proliferation and hypertrophy of astrocytes previously documented in Tg(CJD) mice (Dossena 291 
et al., 2008). Astrocytosis was already observed in the hippocampus of 60-day-old mice, and increased with 292 
age (Figure 3A). Staining with the microglial marker CD11b showed marked microglial activation already at 293 
60 days of age (Figure 3B). 294 
IL-1? immunopositive cells were detected in the hippocampus of Tg(CJD), but not WT and PrP KO mice 295 
(Figure 4A). There were gradually more of these cells in older Tg(CJD) mice (Figure 4B). Co-296 
immunofluorescent staining of IL-1? with GFAP, CD11b, or the neuronal marker NeuN (not shown), showed 297 
that IL-1? was exclusively expressed by astrocytes (Figure 4C). Quantitative RT-PCR showed a significant 298 
increase in IL-1? mRNA in the hippocampus of Tg(CJD) mice already at 60 days of age (Figure 4D). 299 
These results indicate proinflammatory changes in the hippocampus of Tg(CJD) mice starting from a 300 
presymptomatic stage. This proinflammatory milieu, and particularly IL-1? released from activated astrocytes, 301 
may promote neuronal GluN2B phosphorylation over the level induced by loss of PrP function in PrP KO 302 
mice. This may contribute to enhancing NMDAR activity in the mutant mice (Viviani et al., 2003). 303 
The IL-1 receptor antagonist rescues the defect in hippocampal metaplasticity and the age-304 
dependent increase in LTP in Tg(CJD) mice. IL-1? signaling participates in the regulation of synaptic 305 
plasticity in physiological and pathological conditions (Ross et al., 2003; Costello et al., 2011; Vezzani and 306 
Viviani, 2015). To investigate whether the age-dependent elevation of IL-1? in Tg(CJD) mice was associated 307 
with changes in hippocampal synaptic plasticity, we analyzed LTP and metaplasticity in ?300-day-old mice. 308 
TBS resulted in efficient LTP in WT mice (129 ± 5% of baseline, 10 mice, p < 0.01; Figure 5A). LTP was 309 
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significantly reduced in slices from PrP KO mice (106 ± 5%, 13 mice, p > 0.05; Figure 5A), consistent with 310 
the age-dependent impairment in LTP previously documented in these mice (Curtis et al., 2003). In contrast, 311 
in Tg(CJD) animals TBS triggered a greater LTP than in WT controls (171 ± 12%, 5 mice, p < 0.05; Figure 312 
5A), indicating enhanced synaptic responsiveness.  313 
When we examined synaptic metaplasticity, we found that the priming stimulus efficiently suppressed 314 
LTP in slices from WT animals (107 ± 5% of baseline, 7 mice, p > 0.05), but failed to abolish it in Tg(CJD) 315 
mice (145 ± 8%, 5 mice, p < 0.01; Figure 5B), similar to what was seen at ?100 days. In ?300-day-old PrP 316 
KO mice we could not detect any metaplastic phenomena (107 ± 6%, 5 mice, p > 0.05), due to impaired LTP 317 
even in the absence of LFS (Figure 5B). Like in ?100-day-old animals, the priming protocol did not modify 318 
the basal synaptic responses per se (Figure 5B).  319 
Next we tested whether blocking IL-1? signaling could correct the abnormal plasticity in Tg(CJD) mice. 320 
Bath application of anakinra, the human recombinant IL-1 receptor type 1 antagonist (IL-1Ra), on brain slices 321 
from Tg(CJD) mice reduced the LTP to a level comparable to that of WT controls (133 ± 6% of baseline, 5 322 
mice, p < 0.05; Figure 5C). IL-1Ra also normalized metaplasticity in the mutant mice (100 ± 7%, 6 mice, p > 323 
0.05), restoring the effectiveness of the priming protocol in preventing the induction of LTP (Figure 5D). 324 
These results indicate that IL-1? contributes to the metaplastic abnormalities and the age-dependent 325 
increase in hippocampal synaptic responsiveness in Tg(CJD) mice. 326 
Tg(CJD) mice have enhanced susceptibility to kainate-induced seizures which depends on IL-1? 327 
signaling. Since IL-1?, by promoting SFK activation and GluN2B phosphorylation (Viviani et al., 2003), has 328 
proconvulsive effects (Balosso et al., 2008; Galic et al., 2008), we tested whether the Tg(CJD) mice were 329 
more prone to seizures. Focal-onset acute seizures were induced by unilateral intrahippocampal injection of 330 
KA in Tg(CJD), PrP KO and WT mice aged between 210 and 310 days. EEG recordings showed there were 331 
more seizures, and longer time in ictal activity in Tg(CJD) than in PrP KO and WT mice (Figure 6A-C). To 332 
test the contribution of IL-1? signaling in this seizure susceptibility, we injected Tg(CJD) mice with IL-1Ra 333 
(0.5 ?g in 0.5 ?L, intracerebroventricularly) 10 min before intrahippocampal KA. The number of seizures and 334 
time in ictal activity were significantly reduced in Tg(CJD) but not in WT mice (Figure 6D and E). 335 
To exclude that differences in rearing conditions between commercial WT mice and Tg(CJD) and PrP KO 336 
mice raised in-house could affect the results, we compared the susceptibility to kainate-induced seizures of 337 
C57BL/6J adult male mice purchased from our external provider and exposed to seizures two weeks after 338 
arrival in our animal facility, to that of mice of the same strain, age and sex that were born and raised in-339 
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house (7 mice/group). We found no significant differences in time to seizure onset, number of seizures and 340 
time in seizure between the two groups (WT raised in-house: 10.0 ± 4.0 min; 7.9 ± 2.3; 6.7 ± 2.3 min; WT 341 
from Envigo: 8.0 ± 2.6 min; 6.9 ± 3.7; 5.0 ± 1.8 min; mean ? SD). 342 
 343 
 344 
Discussion 345 
The present study found that Tg(CJD) mice, which express a misfolded mutant PrP, had alterations in 346 
hippocampal metaplasticity and an age-related increase in the magnitude of LTP. They also had high levels 347 
of phosphorylated GluN2B, indicative of enhanced NMDAR activity, and were intrinsically more susceptible 348 
to hippocampal seizures. Subtle alterations in synaptic metaplasticity and a modest increase in GluN2B 349 
phosphorylation were also seen in PrP KO mice. However, these mice had an age-dependent decrease in 350 
LTP, and no alterations in hippocampal seizure susceptibility. Tg(CJD) mice had proinflammatory changes, 351 
with progressive astro- and micro-gliosis, and more IL-1?-positive astrocytes in the hippocampus. Blocking 352 
IL-1? signaling rescued the abnormalities in metaplasticity and the age-related increase in LTP, and 353 
significantly reduced susceptibility to seizures. 354 
These findings indicate an enhancement of NMDA-dependent synaptic signaling in the Tg(CJD) 355 
hippocampus which may result from a combination of loss and gain of function of mutant PrP, and involves 356 
neuroinflammation. They suggest that anti-inflammatory drugs that block IL-1? signaling, perhaps in 357 
combination with NMDAR antagonists, may help normalize hippocampal synaptic activity, with beneficial 358 
effects on the symptomatic expression of disease. 359 
Tg(CJD) and PrP KO mice develop similar and divergent abnormalities in hippocampal synaptic 360 
plasticity. In hippocampal slices from ~100-day-old Tg(CJD) mice LTP was normal at the CA3-CA1 361 
synapses but there was an inversion of metaplasticity, with a significant increase in phosphorylation of the 362 
NMDAR GluN2B subunit at tyrosine residue 1472. Phosphorylation at this C-terminal regulatory site prevents 363 
endocytosis of GluN2B, enhancing its cell surface expression and NMDAR activity (Salter and Kalia, 2004). 364 
In the hippocampus, low-frequency (10-Hz) presynaptic stimulation triggers NMDA-dependent metaplastic 365 
changes that inhibit the induction of LTP (Zhang et al., 2005). This homeostatic control may serve to prevent 366 
LTP from occurring too readily in response to weak stimuli, or to restrain LTP induction after strong stimuli, 367 
thus helping maintain synaptic efficacy within a dynamic range permissive for a learning-ready state and 368 
memory retention (Abraham, 2008). The GluN2B-type NMDARs mediate maximal increases in intracellular 369 
Ca2+ in response to low-frequency stimulation, while GluN2A-type receptors activate maximally in response 370 
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to high-frequency synaptic inputs (Erreger et al., 2005). The hyper-phosphorylation of GluN2B in Tg(CJD) 371 
mice may change the biophysical properties of NMDAR, with consequent alterations in post-synaptic Ca2+ 372 
dynamic and downstream Ca2+-dependent signaling after the 10-Hz priming stimulus. This may lead to 373 
inversion of metaplasticity without affecting LTP, and potentially contribute to the memory impairment that 374 
develops in these mice (Dossena et al., 2008). 375 
There was a modest increase in phospho-Tyr1472 GluN2B in PrP KO mice. There is evidence that PrP 376 
participates in a signaling cascade that activates SFK Fyn and promotes GluN2B phosphorylation (Um et al., 377 
2012), and loss of PrP may result in constitutive activation of this signaling. We have also found that PrP 378 
interacts physically with GluN2B (manuscript in preparation), possibly promoting its intracellular transport, or 379 
acting as a scaffold protein to target the receptor to specific microdomains of the synaptic membrane 380 
(Senatore et al., 2013). GluN2B may be hyperphosphorylated in PrP KO mice as an adaptive response to 381 
permit interaction with other proteins that favor its cell surface expression (Maier et al., 2013). The modest 382 
increase of phospho-Tyr1472 GluN2B in the hippocampus of PrP KO mice, however, does not appear to 383 
have important functional consequences, since metaplasticity is only slightly altered, and mice are not 384 
impaired in hippocampus-dependent learning and memory (Dossena et al., 2008; Bouybayoune et al., 2015) 385 
(and unpublished data). Other mechanisms should therefore presumably be operative in Tg(CJD) mice that 386 
raise GluN2B phosphorylation over the level induced by loss of PrP, leading to hippocampal dysfunction. 387 
We previously reported that PrP deposition in the brains of Tg(CJD) mice was associated with prominent 388 
hypertrophy and proliferation of astrocytes in the hippocampus (Dossena et al., 2008). We have now shown 389 
that microglia are also activated, and that both micro- and astro-gliosis prefigure the appearance of 390 
neurological deficits and increase further during the symptomatic phase of the disease, most likely reflecting 391 
the progressive accumulation of misfolded PrP (Bouybayoune et al., 2015). The novel information is that 392 
hippocampal IL-1? is specifically raised in astrocytes, in accordance with previous evidence of high whole-393 
tissue levels in variant and sporadic CJD and in CJD-infected mice (Kordek et al., 1996; Sharief et al., 1999; 394 
Shi et al., 2013; Llorens et al., 2014). 395 
The mechanism by which misfolded mutant PrP triggers IL-1? biosynthesis in astroglial cells in vivo is not 396 
known. Application of the neurotoxic PrP106-126 peptide to cultured astrocytes and microglial cells 397 
stimulates their proliferation and IL-1? release through the activation of NF-kB (Forloni et al., 1994; Hafiz and 398 
Brown, 2000; Lu et al., 2012), suggesting that the misfolded PrP in the brains of Tg(CJD) mice may have a 399 
similar effect. 400 
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Electrophysiological analysis detected a dramatic increase in hippocampal LTP magnitude in ?300-day-401 
old Tg(CJD) mice, and weakened LTP in PrP KO littermates, clearly differentiating the effects of mutant PrP 402 
from those of PrP deletion. At this age, we saw a marked increase of IL-1?-positive astrocytes in the 403 
Tg(CJD) hippocampus. IL-1? dose-dependently induced GluN2B phosphorylation in cultured hippocampal 404 
neurons through activation of SFK, and this effect was abolished by the IL-1 receptor antagonist (Viviani et 405 
al., 2003). Consistent with a role of IL-1? in altering NMDAR responses in Tg(CJD) mice, IL-1Ra restored 406 
normal LTP and rescued the metaplastic defect in brain slices. 407 
Hypersynchronous hippocampal bursting caused by enhanced NMDAR-mediated excitation has been 408 
reported in mice infected with vCJD prions (Ratte et al., 2008). In the light of the high IL-1? levels in vCJD 409 
patients (Sharief et al., 1999), it may be worth measuring this cytokine in the brain of vCJD-infected mice and 410 
test whether anakinra prevents these hypersynchronous hippocampal bursting. 411 
LTP was significantly impaired in ?300-day-old PrP KO mice. An age-related alteration in hippocampal 412 
LTP was previously reported in Zürich I PrP KO mice (the strain also used in our study), and in an 413 
independently generated line of co-isogenic 129/Ola mice in which the Prnp locus was disrupted using a 414 
different strategy (Curtis et al., 2003). However, analysis of hippocampal synaptic plasticity in PrP KO mice 415 
has produced conflicting results (Collinge et al., 1994; Manson et al., 1995; Lledo et al., 1996; Maglio et al., 416 
2004, 2006). Differences in the induction protocol, animal model and/or age of the mice may account for 417 
these. Zürich I mice, as well as mice in which PrP was postnatally ablated only in neurons, also had a 418 
significant attenuation of after-hyperpolarization potentials (AHPs) in CA1 pyramidal neurons (Colling et al., 419 
1996; Mallucci et al., 2002), supporting a direct role for PrP in hippocampal excitability.  420 
Tg(CJD) but not PrP KO mice show enhanced susceptibility to hippocampal seizures which depends 421 
on IL-1? signaling. Tg(CJD) mice were intrinsically more susceptible to hippocampal seizures, suggesting a 422 
low seizure threshold. The competitive IL-1R type 1 antagonist IL-1Ra significantly blocked this effect, 423 
indicating that it was mediated by the endogenous IL-1? which was increased in Tg(CJD) mouse 424 
hippocampus. In full accordance with this, there is evidence that intra-hippocampally injected IL-1? increases 425 
kainate seizures – and other types of seizures – in rodents (Vezzani et al., 1999, 2000; Maroso et al., 2011; 426 
Iori et al., 2017), and IL-1? pro-ictogenic effects were blocked by IL-1Ra (Vezzani et al., 1999, 2000). Gliosis 427 
was attenuated, disease onset was delayed and survival was significantly prolonged in prion-infected mice 428 
lacking IL-1R type 1 (Schultz et al., 2004; Tamguney et al., 2008). IL-1?’s effects on seizures are mediated 429 
by Src family kinase phosphorylation of GluN2B which promotes neuronal Ca2+ influx (Viviani et al., 2003; 430 
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Balosso et al., 2008). Since IL-1? is increased in the brain and CSF of CJD patients, this may contribute to 431 
the synaptic alterations and seizures in patients in the advanced stages of the disease (Wieser et al., 2006). 432 
These data support the idea that anakinra, or other anti-IL-1? drugs, might have therapeutic effects in prion 433 
diseases. 434 
At variance with previous observations (Walz et al., 1999; Rangel et al., 2007), we found no difference in 435 
susceptibility to seizures between PrP KO and WT mice; this might be due to focal rather than systemic 436 
administration of KA, the latter also involving extra hippocampal brain regions contributing to seizures. In 437 
addition, we used mice with a homogeneous C57BL/6J background, whereas other studies used PrP KO 438 
mice with mixed genetic backgrounds (typically 129Sv X C57BL/6J), and genetic heterogeneity may 439 
profoundly affect seizure susceptibility in mice (Schauwecker, 2011; Striebel et al., 2013a, 2013b). 440 
Animal husbandry and rearing conditions can also affect susceptibility to seizures (Leussis and Heinrichs, 441 
2006, 2009), and our C57BL/6J controls were purchased from an external provider whereas the Tg(CJD) 442 
and PrP KO mice were raised in-house. However, this difference is unlikely to have affected our results since 443 
we found no differences in seizure susceptibility between C57BL/6J mice purchased from Envigo and those 444 
that were born and raised in-house. Moreover, all mice from the external vendor were housed for at least two 445 
weeks in our animal facilities together with Tg(CJD) and PrP KO mice before being used for the experiments. 446 
In summary, we provide evidence of dysfunctional NMDA-dependent hippocampal synaptic plasticity and 447 
enhanced seizure susceptibility in Tg(CJD) mice. These effects appear to result from altered NMDAR activity 448 
and neuroinflammation. Targeting NMDAR and IL-1? signaling with clinically available drugs may be 449 
beneficial in the symptomatic treatment of the disease. 450 
 451 
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Figure legends 714 
Figure 1. Young adult Tg(CJD) mice have normal hippocampal plasticity but abnormal metaplasticity. 715 
(A) Theta burst stimulation (TBS) of Schaffer collaterals induces significant long-term potentiation (LTP) of 716 
field post-synaptic potentials (fPSP) responses in CA1 of ?100-day-old WT mice (white circles; RM1W, F7,9 = 717 
30, p = 0.0003; Tukey’s p < 0.05). LTP was similar in age-matched PrP KO (grey circles; RM1W, F8,9 = 26, p 718 
= 0.0004; Tukey’s p < 0.05) and Tg(CJD) mice (green circles; RM1W, F6,9 = 18, p = 0.005; Tukey’s p < 0.05) 719 
(RM2W, F2,21 = 0.7, p = 0.7; WT vs. CJD, p > 0.05, Tukey’s post hoc test). Insets, superimposed averaged 720 
records (5 traces) from WT (left) PrP KO (center) and Tg(CJD) (right) mice before (gray line) and 35-45 min 721 
after the TBS stimulation (red line). (B) Preceding the TBS with a priming stimulation (2 trains of 10 pulses at 722 
10Hz, spaced 1 second apart) prevented the LTP in WT mice (white circles; RM1W, F6,9 = 0.4, p = 0.6) but 723 
not in PrP KO (grey circles; RM1W, F9,9 = 13, p = 0.003; Tukey’s p < 0.05) or Tg(CJD) mice (green circles; 724 
RM1W, F8,9 = 22, p = 0.001; Tukey’s p < 0.05) (RM2W, F2,23 = 0.9, p = 0.5; WT vs. KO, p > 0.05; WT vs. CJD, 725 
p < 0.001; KO vs. CJD, p < 0.5, Tukey’s post hoc test). The priming stimulus did not significantly alter the 726 
fPSP slope in Tg(CJD) mice compared to controls (WT: 100 ± 4% of baseline, 7 mice, RM1W, F6,8 = 0.5, p = 727 
0.5; PrP KO: 99 ± 2% of baseline, 10 mice, RM1W, F9,8 = 0.2, p = 0.7; Tg(CJD): 111 ± 4% of baseline, 9 728 
mice, RM1W, F8,9 = 7, p = 0.02; Tukey’s p > 0.05) (RM2W, F2,23 = 1.0, p = 0.5; WT vs. PrP KO, p > 0.05; WT 729 
vs. Tg(CJD), p > 0.05, Tukey’s post hoc test). Insets, superimposed averaged records (5 traces) from WT 730 
(left) PrP KO (center) and Tg(CJD) (right) mice before the priming stimulus (gray line), 18-26 min after the 731 
low-frequency priming stimulus (LFS) (blue line) and 35-45 min after the TBS (red line). (A, B) Averaged 732 
time courses (mean ± SEM) of normalized fPSP slopes. TBS or LFS (in the metaplasticity experiments) were 733 
done at the red and the black arrows, respectively. Dashed horizontal lines define baseline responses. 734 
 735 
Figure 2. Increased phospho-Tyr GluN2B  in hippocampal post-synaptic fractions of Tg(CJD) and PrP 736 
KO mice. (A) Triton X-100 insoluble fractions representing the post-synaptic density were isolated from the 737 
hippocampi of WT, KO and Tg(CJD) mice. Samples corresponding to 10 ?g of protein were analyzed by 738 
Western blot with the antibodies indicated. (B) The protein levels were quantified by densitometric analysis 739 
of Western blots, normalized for the level of actin and expressed as percentages of the level in WT mice. (C) 740 
Tyrosin 1472-phosphorylated GluN2B was normalized on total GluN2B, and expressed as percentages of 741 
the level in WT mice. Data are the mean ? SEM of 8-10 animals at 65-80 days of age; F2,86 = 6.541 p = 742 
0.0023 by one-way ANOVA; **p < 0.01 vs. WT by Tukey’s post hoc test. 743 
 744 
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Figure 3. Tg(CJD) mice have proliferation of astrocytes and microglia in the hippocampus. (A) Brain 745 
sections from Tg(CJD) mice at the ages indicated were stained with anti-glial fibrillar acidic protein (GFAP) 746 
antibody. Immunostaining revealed marked astrocytosis in the hippocampus. (B) Immunostaining with anti-747 
CD11b shows marked microgliosis in the hippocampus of a Tg(CJD) mouse at 60 days of age compared to 748 
an age-matched WT control. Scale bars: 100 ?m.CA1, field CA1 of hippocampus;h, hilus of the dentate 749 
gyrus.Insets: high magnification of resting (WT) and activated (CJD) microglia. 750 
 751 
Figure 4. Tg(CJD) mice have an age-related increase in IL-1?-positive astrocytes in the hippocampus. 752 
(A) Brain sections from the Tg(CJD), WT and PrP KO mice of the ages indicated were immunostained with 753 
anti-IL-1? antibody and nickel-intensified diaminobenzidine. Scale bar: 100 ?m. Inset: high magnification of 754 
IL-1?-positive cells. (B) The IL-1?-immunopositive cells in the hippocampus of the mice of different 755 
genotypes and ages were counted and expressed as the -fold change over the numbers in WT mice. Data 756 
are mean ? SEM of 4-6 animals (2-3 brain sections each); F4,18 = 22.20 p < 0.0001 by one-way ANOVA; ***p 757 
< 0.001; ****p < 0.0001 vs. WT and KO by Tukey’s post hoc test. (C) Immunofluorescence staining of IL-1? 758 
(red) and glial fibrillary acidic protein (GFAP) or CD11b (green) in the dentate gyrus of the hippocampus of a 759 
Tg(CJD) mouse at 72 days of age. Sections were reacted with Hoechst 33258 to stain the cell nuclei (blue). 760 
The merged images show co-localization of IL-1? with GFAP, but not with CD11b. Scale bar: 10 ?m. (D) 761 
Total RNA was extracted from the hippocampi of 60-66 day-old WT, PrP KO and Tg(CJD) mice, and 762 
analyzed by RT-qPCR for IL-1? and GAPDH. mRNAs were quantified by the ??Ct method and expressed as 763 
the -fold increase over WT. Data are the mean ± SEM of 4-5 animals per group; F2,17 = 4.506 p = 0.0269 by 764 
one-way ANOVA; *p < 0.05 vs. WT and KO by Holm-Sidak’s post hoc test. 765 
 766 
Figure 5. Aged Tg(CJD) mice have altered hippocampal plasticity and metaplasticity, which are 767 
normalized by IL-1 receptor antagonism. (A) Theta burst stimulation (TBS) induces LTP at the CA3-CA1 768 
synapses of ?300-days-old WT mice (gray circles; RM1W, F9,9 = 36, p < 0.0001; Tukey’s p < 0.01). The 769 
same protocol fails to induce LTP in brain slices of age-matched PrP KO mice (dark grey circles; RM1W, 770 
F12,9 = 1.6, p = 0.2). In slices from Tg(CJD) mice, TBS results in LTP (light green circles; RM1W, F4,9 = 31, p 771 
= 0.003; Tukey’s p < 0.05) larger than in controls (RM2W, F2,25 = 0.9, p = 0.6; WT vs. KO, p < 0.05, WT vs. 772 
CJD, p < 0.001; KO vs. CJD, p < 0.001; Tukey’s post hoc test). Insets: superimposed averaged records (5 773 
traces) from WT (left) PrP KO (center) and Tg(CJD) (right) mice before (gray line) and 35-45 min after the 774 
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TBS (red line).  (B) Upon LFS priming, LTP was absent in WT mice (gray circles; RM1W, F6,9 = 3, p = 0.1) 775 
and PrP KO mice (dark grey circles; RM1W, F4,9 = 1, p = 0.4), but not in Tg(CJD) mice (light green circles; 776 
RM1W, F4,9 = 28, p = 0.0024; Tukey’s p < 0.01) (RM2W, F2,14 = 0.6, p = 0.7; WT vs. KO, p > 0.05, WT vs 777 
CJD, p < 0.001; KO vs. CJD, p < 0.001; Tukey’s post hoc test).  The priming stimulus did not significantly 778 
alter fPSP responses in Tg(CJD) mice compared to controls (WT: 92 ± 5% of baseline, 7 mice, RM1W, F6,8 = 779 
1.3, p = 0.3; PrP KO: 98 ± 5% of baseline, 5 mice, RM1W, F4,8= 0.4, p = 0.6; Tg(CJD): 104 ± 3% of baseline, 780 
5 mice, RM1W, F4,8 = 16, p = 0.001; Tukey’s p > 0.05 ) (RM2W, F2,14 = 1.6, p = 0.1; WT vs. KO, p > 0.05; WT 781 
vs CJD, p > 0.05; Tukey’s post hoc test). Insets: superimposed averaged records (5 traces) from WT (left) 782 
PrP KO (center) and Tg(CJD) (right) mice before the priming stimulus (gray line), 15-25 min after the LFS 783 
(blue line), and 35-45 min after the TBS (red line). (A,B) Averaged time courses (mean ± SEM) of normalized 784 
fPSP slopes. TBS or LFS (in the metaplasticity experiments) were done at the red and the black arrows, 785 
respectively. Dashed horizontal lines define baseline responses. (C) Bath application of IL1-Ra reduced the 786 
magnitude of LTP in Tg(CJD) mice (brown circles; RM1W, F4,9 = 22, p = 0.0055; Tukey’s p < 0.05; the green 787 
line from panel A is reported here for comparison) to levels comparable to WT mice (black line, reported from 788 
panel A for comparison) (RM2W, F2,17 = 0.9, p = 0.5; CJD + IL-1Ra vs. CJD, p < 0.05; CJD + IL-1Ra vs. WT, 789 
p > 0.05; Tukey’s post hoc test). Inset, superimposed averaged records (5 traces) from CJD + IL-1Ra before 790 
(gray line) and 35-45 min after the TBS (red line). (D) Upon bath application of IL-1Ra, the LFS priming 791 
protocol prevented LTP in Tg(CJD) mice (brown circles; RM1W, F5,9 = 0.2, p = 0.7; the green line from panel 792 
B is reported here for comparison), similarly to WT controls (black line, reported from panel B for 793 
comparison) (RM2W, F2,15 = 1.5, p = 0.2; CJD + IL-1Ra vs. CJD, p < 0.05; CJD + IL-1Ra vs. WT, p > 0.05; 794 
Tukey’s post hoc test). The priming stimulus did not significantly alter the fPSP responses in CJD mice (94 ± 795 
6% of baseline, 6 mice, RM1W, F5,8 = 1.2, p = 0.3) compared to controls (RM2W, F2,15 = 0.9, p = 0.6; CJD + 796 
IL-1Ra vs. CJD, p > 0.05; CJD + IL-1Ra vs. WT, p > 0.05; Tukey’s post hoc test). Inset: superimposed 797 
averaged records (5 traces) from CJD + IL-1Ra before the priming stimulus (gray line), 18-26 min after the 798 
LFS (blue line) and 35-45 min after the TBS (red line). (C,D) Averaged time courses (mean ± SEM) of 799 
normalized fPSP amplitudes. TBS or LFS (in the metaplasticity experiments) were done at the red and the 800 
black arrows, respectively. Dashed horizontal lines define baseline responses. 801 
 802 
Figure 6. Tg(CJD) mice have increased susceptibility to kainate-induced seizures, which depends on 803 
IL-1? signaling. (A) Representative EEG tracings depicting baseline recordings (top) and ictal activity after 804 
intrahippocampal kainic acid (KA) injection (bottom) in the left (LHP) and right (RHP) hippocampus in freely 805 
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moving mice. (B, C) Number of seizures and time spent in seizures in WT (8), PrP KO (9) and Tg(CJD)(6) 806 
mice injected with KA. Data are mean ± SEM; **p<0.01 vs. WT and KO mice by one-way ANOVA (F2,20 = 807 
19.41 in B and F2,20 = 17.25 in C, p < 0.0001) followed by Tukey’s test. (D, E) Number of seizures and time 808 
spent in seizures in WT and Tg(CJD) mice injected with IL-1Ra (anakinra) or saline (intracerebroventricularly 809 
and bilaterally; 0.5 ?g in 0.5 ?L/side), 10 min before KA. Data are mean ± SEM (9-10 each group); **p < 0.01 810 
vs WT and #p < 0.05 vs. Tg(CJD) + saline by Mann-Whitney test (p = 0.0102 in D and p = 0.0133 in E, 811 
Tg(CJD)+IL-1Ra vs Tg(CJD)). 812 






